PortfoliosLab logo
ADMA vs. NVDA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ADMA and NVDA is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

ADMA vs. NVDA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ADMA Biologics, Inc. (ADMA) and NVIDIA Corporation (NVDA). The values are adjusted to include any dividend payments, if applicable.

0.00%10,000.00%20,000.00%30,000.00%40,000.00%December2025FebruaryMarchAprilMay
147.95%
31,924.56%
ADMA
NVDA

Key characteristics

Sharpe Ratio

ADMA:

2.94

NVDA:

0.51

Sortino Ratio

ADMA:

3.65

NVDA:

1.02

Omega Ratio

ADMA:

1.48

NVDA:

1.13

Calmar Ratio

ADMA:

4.58

NVDA:

0.74

Martin Ratio

ADMA:

13.73

NVDA:

1.85

Ulcer Index

ADMA:

15.07%

NVDA:

14.81%

Daily Std Dev

ADMA:

71.91%

NVDA:

59.43%

Max Drawdown

ADMA:

-91.28%

NVDA:

-89.73%

Current Drawdown

ADMA:

-13.50%

NVDA:

-21.45%

Fundamentals

Market Cap

ADMA:

$5.61B

NVDA:

$2.79T

EPS

ADMA:

$0.81

NVDA:

$2.94

PE Ratio

ADMA:

29.04

NVDA:

38.95

PEG Ratio

ADMA:

0.00

NVDA:

1.61

PS Ratio

ADMA:

13.26

NVDA:

21.28

PB Ratio

ADMA:

16.08

NVDA:

35.22

Total Revenue (TTM)

ADMA:

$344.58M

NVDA:

$104.45B

Gross Profit (TTM)

ADMA:

$180.30M

NVDA:

$77.45B

EBITDA (TTM)

ADMA:

$123.41M

NVDA:

$68.38B

Returns By Period

In the year-to-date period, ADMA achieves a 23.62% return, which is significantly higher than NVDA's -12.59% return. Over the past 10 years, ADMA has underperformed NVDA with an annualized return of 10.56%, while NVDA has yielded a comparatively higher 72.94% annualized return.


ADMA

YTD

23.62%

1M

18.70%

6M

7.51%

1Y

209.04%

5Y*

54.63%

10Y*

10.56%

NVDA

YTD

-12.59%

1M

21.88%

6M

-21.15%

1Y

29.85%

5Y*

72.35%

10Y*

72.94%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ADMA vs. NVDA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ADMA
The Risk-Adjusted Performance Rank of ADMA is 9797
Overall Rank
The Sharpe Ratio Rank of ADMA is 9999
Sharpe Ratio Rank
The Sortino Ratio Rank of ADMA is 9797
Sortino Ratio Rank
The Omega Ratio Rank of ADMA is 9696
Omega Ratio Rank
The Calmar Ratio Rank of ADMA is 9999
Calmar Ratio Rank
The Martin Ratio Rank of ADMA is 9797
Martin Ratio Rank

NVDA
The Risk-Adjusted Performance Rank of NVDA is 7171
Overall Rank
The Sharpe Ratio Rank of NVDA is 7171
Sharpe Ratio Rank
The Sortino Ratio Rank of NVDA is 6666
Sortino Ratio Rank
The Omega Ratio Rank of NVDA is 6565
Omega Ratio Rank
The Calmar Ratio Rank of NVDA is 7979
Calmar Ratio Rank
The Martin Ratio Rank of NVDA is 7272
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ADMA vs. NVDA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current ADMA Sharpe Ratio is 2.94, which is higher than the NVDA Sharpe Ratio of 0.51. The chart below compares the historical Sharpe Ratios of ADMA and NVDA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.008.00December2025FebruaryMarchAprilMay
2.94
0.51
ADMA
NVDA

Dividends

ADMA vs. NVDA - Dividend Comparison

ADMA has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.03%.


TTM20242023202220212020201920182017201620152014
ADMA
ADMA Biologics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVDA
NVIDIA Corporation
0.03%0.02%0.03%0.11%0.05%0.12%0.27%0.46%0.29%0.45%1.20%1.70%

Drawdowns

ADMA vs. NVDA - Drawdown Comparison

The maximum ADMA drawdown since its inception was -91.28%, roughly equal to the maximum NVDA drawdown of -89.73%. Use the drawdown chart below to compare losses from any high point for ADMA and NVDA. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%December2025FebruaryMarchAprilMay
-13.50%
-21.45%
ADMA
NVDA

Volatility

ADMA vs. NVDA - Volatility Comparison

ADMA Biologics, Inc. (ADMA) has a higher volatility of 25.35% compared to NVIDIA Corporation (NVDA) at 22.46%. This indicates that ADMA's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%December2025FebruaryMarchAprilMay
25.35%
22.46%
ADMA
NVDA

Financials

ADMA vs. NVDA - Financials Comparison

This section allows you to compare key financial metrics between ADMA Biologics, Inc. and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0010.00B20.00B30.00B40.00BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
117.55M
39.33B
(ADMA) Total Revenue
(NVDA) Total Revenue
Values in USD except per share items

ADMA vs. NVDA - Profitability Comparison

The chart below illustrates the profitability comparison between ADMA Biologics, Inc. and NVIDIA Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-50.0%0.0%50.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
53.9%
73.0%
(ADMA) Gross Margin
(NVDA) Gross Margin
ADMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a gross profit of 63.33M and revenue of 117.55M. Therefore, the gross margin over that period was 53.9%.

NVDA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, NVIDIA Corporation reported a gross profit of 28.72B and revenue of 39.33B. Therefore, the gross margin over that period was 73.0%.

ADMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported an operating income of 38.32M and revenue of 117.55M, resulting in an operating margin of 32.6%.

NVDA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, NVIDIA Corporation reported an operating income of 24.03B and revenue of 39.33B, resulting in an operating margin of 61.1%.

ADMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, ADMA Biologics, Inc. reported a net income of 111.90M and revenue of 117.55M, resulting in a net margin of 95.2%.

NVDA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, NVIDIA Corporation reported a net income of 22.09B and revenue of 39.33B, resulting in a net margin of 56.2%.